BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 19632367)

  • 1. Proteomics in human Parkinson's disease research.
    Licker V; Kövari E; Hochstrasser DF; Burkhard PR
    J Proteomics; 2009 Nov; 73(1):10-29. PubMed ID: 19632367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. α-Synuclein and Lewy pathology in Parkinson's disease.
    Kalia LV; Kalia SK
    Curr Opin Neurol; 2015 Aug; 28(4):375-81. PubMed ID: 26110807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the Braak hypothesis: how far can it explain the pathogenesis of Parkinson's disease?
    Halliday G; McCann H; Shepherd C
    Expert Rev Neurother; 2012 Jun; 12(6):673-86. PubMed ID: 22650170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Research in motion: the enigma of Parkinson's disease pathology spread.
    Brundin P; Li JY; Holton JL; Lindvall O; Revesz T
    Nat Rev Neurosci; 2008 Oct; 9(10):741-5. PubMed ID: 18769444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heredity in Parkinson's disease: new findings.
    Lev N; Melamed E
    Isr Med Assoc J; 2001 Jun; 3(6):435-8. PubMed ID: 11433638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
    Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?
    Schulz-Schaeffer WJ
    Biomolecules; 2015 Jul; 5(3):1467-79. PubMed ID: 26193328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
    Lee VM; Trojanowski JQ
    Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease.
    Iannaccone S; Cerami C; Alessio M; Garibotto V; Panzacchi A; Olivieri S; Gelsomino G; Moresco RM; Perani D
    Parkinsonism Relat Disord; 2013 Jan; 19(1):47-52. PubMed ID: 22841687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathological roles of α-synuclein in neurological disorders.
    Vekrellis K; Xilouri M; Emmanouilidou E; Rideout HJ; Stefanis L
    Lancet Neurol; 2011 Nov; 10(11):1015-25. PubMed ID: 22014436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controversy: is Parkinson's disease a single disease entity? Yes.
    Takahashi H; Wakabayashi K
    Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S31-7. PubMed ID: 15885626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha-synuclein and Parkinson's disease: a proteomic view.
    Fasano M; Lopiano L
    Expert Rev Proteomics; 2008 Apr; 5(2):239-48. PubMed ID: 18466054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts.
    Jellinger KA
    Mov Disord; 2012 Jan; 27(1):8-30. PubMed ID: 22081500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The mechanism of Lewy body formation in Parkinson's disease].
    Wakabayashi K; Takahashi H
    Nihon Rinsho; 2000 Oct; 58(10):2022-7. PubMed ID: 11068441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteomics in Human Parkinson's Disease: Present Scenario and Future Directions.
    Dixit A; Mehta R; Singh AK
    Cell Mol Neurobiol; 2019 Oct; 39(7):901-915. PubMed ID: 31190159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Drosophila model of Parkinson's disease.
    Feany MB; Bender WW
    Nature; 2000 Mar; 404(6776):394-8. PubMed ID: 10746727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies.
    Oueslati A; Fournier M; Lashuel HA
    Prog Brain Res; 2010; 183():115-45. PubMed ID: 20696318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of oxidative damage in protein aggregation associated with Parkinson's disease and related disorders.
    Norris EH; Giasson BI
    Antioxid Redox Signal; 2005; 7(5-6):672-84. PubMed ID: 15890012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. α-Synuclein aggregation and modulating factors.
    Paleologou KE; El-Agnaf OM
    Subcell Biochem; 2012; 65():109-64. PubMed ID: 23225002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.